ICML 2021 | JACKPOT8: DZD4205 in peripheral T-cell lymphoma
Won-Seog Kim
• 21 Jun 2021
Won-Seog Kim, MD, PhD, Sungkyunkwan University, Seoul, South Korea, discusses preliminary safety and efficacy data from the Phase I/II JACKPOT8 trial (NCT04105010) of DZD4205, a selective JAK1 inhibitor, in patients with peripheral T-cell lymphoma (PTCL). Preliminary tests has shown anti-tumor activity and in the Phase I/II trial, 150 mg or 250 mg of DZD4205 was administered. Whilst efficacy was the same in both doses, the lower dose had fewer adverse effects. Prof. Kim additionally reports a durable response and several grade 3 toxicities in patients receiving DZD4205. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
